StAR related lipid transfer domain containing 6Genealiases: []
Q-omics provides the consensus-scored STARD6 profile across patient tissues and cancer cell-line models. STARD6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, STARD6 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, STARD6 RNA expression shows 14,531 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, HNSC, and KIRP as cancer lineages where STARD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STARD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STARD6 survival associations across molecular data types. STARD6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STARD6 RNA expression–survival associations across cancer types. High STARD6 expression shows unfavorable associations in LIHC, BLCA, ACC and MESO, but favorable associations in PAAD and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for STARD6 RNA expression.
This table summarizes STARD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for STARD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STARD6 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LUSC, BRCA and LIHC. The HNSC box plot shows higher STARD6 RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p < 0.001).
This table shows molecular features associated with STARD6 in patient tissues and cancer cell lines. In patient samples, STARD6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, STARD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
